Havas San Francisco: 2017
Havas San Francisco
1725 Montgomery Street, 13th Floor
San Francisco, CA 94111
Telephone: 415-345-7700
Website: sf.havas.com
Finalist
Best Interactive Patient Campaign
Accounts
Account wins 6
Active business clients 24
Brands by 2016 sales
Brand-product accounts held 24
Services Mix
Consumer digital/web/mobile 40%
Professional digital/web/mobile 30%
Direct marketing 20%
Consumer print ads 10%
“2016 was not just another great year for Havas San Francisco. It was also a ground-breaking year for many of our clients too,” executives say.
The Year’s Accomplishments
“With the launch of MS Voice, we ushered our anchor client Genentech into the social sphere by starting a record-breaking community for multiple sclerosis patients. MS Voice has given this community a forum to talk about their condition and connect on an emotional level. The campaign has been incredibly effective so far, with over 6 million post engagements in the first six months alone. In addition to over 5,000 YouTube views, we’ve seen over 10,000 quiz and poll entries with a 65 percent completion rate.”
All this precedes the launch of the breakthrough Genentech drug Ocrevus, the first drug approved by the FDA to treat severe multiple sclerosis. A new site and multi-channel digital advertising campaign conceived and created by Havas San Francisco will break in early 2017, executives say.
Similar innovations are happening on Genentech’s oncology front as well, according to agency leaders. In March 2017, Havas San Francisco was awarded the Tecentriq patient digital business. “This innovative immunotherapy is changing the oncology treatment landscape across a number of cancer indications,” executives say. “Social and digital will play large roles in taking on this competitive and crowded space.”
In 2016, the agency launched a redesigned Tamiflu.com for Genentech. “Based on an incredible five-year partnership of digital innovation for the brand, the redesign includes consumer-
driven features such as a localized, interactive flu tracker tool and social media-sharable coupons,” agency management says.
“In addition to winning many accolades including an Effie, this franchise has been an incredible ride.”
Agency leaders say another major milestone in 2016 was the relaunch of Esbriet.com, for Esbriet, a Genentech drug that slows the progression of idiopathic pulmonary fibrosis (IPF). “This repositioning and site redesign was grounded in user experience, driven by research insights for reaching and educating an elderly target audience and their caregivers,” Havas San Francisco executives say. “We leveraged an ambassador program through various channels to drive this new benefit home to patients. As we enter 2017, we are increasingly analytics-focused to further refine brand digital initiatives.”
In 2016 the agency also continued to support many of Genentech’s portfolio of brands including Herceptin, Kadcyla, Perjeta, Nutropin, Pulmozyme, Tarceva, Lucentis, Genentech Access Solutions, and several programs in clinical development, executives say.
“This year also welcomed the arrival of our newest client, BioMarin Pharmaceutical,” execs say. “We got off to quick start and launched their PKU unbranded campaign with a host of new original content, including a revamped social media presence that is supporting patients in this rare disease community. We have big plans for 2017 with the rollout of new patient and professional sites for both the PKU disease state as well as BioMarin’s flagship PKU drug, Kuvan, and new communications programs for patients and healthcare professionals that will provide touchpoints for PKU education and ongoing support.”
Structure & Services
“Internally, our office is pleased to announce that we are now part of the newly formed Havas Health & You, a global network of health and wellness expertise,” according to agency management. “In today’s quickly evolving world, the power to deal with a medical situation is increasingly in the hands of patients and their caregivers. Hence, our desire to include them in our thinking,” says Havas San Francisco CEO Alan Burgis, “Out of this insight was born Havas Health & You. Timely, relevant, and powerful.”
Future Plans
“This development, coupled with the addition of a social media director and a patient experience director in our office, make us well-poised to take on 2017,” management says.
